Compass Pathways plc, a biotechnology company committed to enhancing mental health treatment access, has appointed Kathleen Tregoning to its Board of Directors during its annual general meeting. Tregoning, who will serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee, brings a wealth of experience from her previous roles at Cerevel Therapeutics and Sanofi, where she oversaw corporate strategy and public policy. With Compass Pathways advancing its investigational COMP360 psilocybin treatment for treatment-resistant depression, Tregoning's expertise is expected to be invaluable as the company aims for FDA approval. CEO Kabir Nath highlighted the significance of her experience in external engagement and patient access as Compass prepares for regulatory review. Tregoning expressed her commitment to supporting the company's mission, emphasizing the critical need for new mental health treatment options. Compass Pathways, headquartered in London with a U.S. office in New York, is pioneering innovative approaches to mental health care, aiming to provide effective solutions for those underserved by existing treatments.